The shedding of ectodomains is a crucial mechanism in many physiological and pathological events. A disintegrin and metalloprotease-17 (ADAM17) is a key sheddase involved in essential processes, such as development, regeneration, and immune defense. ADAM17 exists in two conformations which differ in their disulfide connection in the membrane-proximal domain (MPD). Protein-disulfide isomerases (PDIs) on the cell surface convert the open MPD into a rigid closed form, which corresponds to inactive ADAM17. ADAM17 is expressed in its open activatable form in the endoplasmic reticulum (ER) and consequently must be protected against ER-resident PDI activity. Here, we show that the chaperone 78-kDa glucose-regulated protein (GRP78) protects the MPD against PDI-dependent disulfide-bond isomerization by binding to this domain and, thereby, preventing ADAM17 inhibition.
(TNF-a) [1, 2] and the interleukin-6 receptor (IL-6R) [3] , but also growth factors and adhesion molecules that are proteolytically cleaved and thereby released from the cell surface [4] . This ectodomain shedding leads to the down-regulation of proteins from the cell surface and also initiates or inhibits autocrine or paracrine signaling by the generation of soluble ectodomains. The importance of ectodomain shedding is highlighted by the gene deletion of ADAM17 in mice, an event that leads to perinatal lethality [5] . Experiments with ADAM17 conditional knock-out mice [6] and hypomorphic ADAM17 knock-in mice [7] have demonstrated that ADAM17 is a molecular switch in development, regeneration processes, and cancer development and in immune responses and uncontrolled inflammation. Therefore, ADAM17 activity is strictly regulated at multiple levels [8] .
ADAM17 is a type-I transmembrane multidomain protein, consisting of an N-terminal signal peptide and a pro-, a metalloproteinase-, a disintegrin-, and a membrane-proximal domain (MPD) followed by a region named Conserved ADAM seventeeN Interaction Sequence (CANDIS), a single transmembrane region, and a cytoplasmic tail [9] [10] [11] [12] . In the mature protease, the inhibitory prodomain is split off, and the N-terminal-located catalytic domain is able to cleave substrates [13, 14] . The remaining ectodomain and the cytoplasmic tail are needed for substrate recognition and regulation. In contrast to its closest relative ADAM10, ADAM17 needs to be activated to gain shedding activity. Nevertheless, the underlying mechanisms are still not well understood [15, 16] . The cytoplasmic region of ADAM17 is involved in regulation events such as protein trafficking [17] and activation [18, 19] but is apparently not needed for phorbol 12-myristate 13-acetate (PMA)-or src-activated shedding [20, 21] . Indeed, many reports have claimed that regulated trafficking to the cell surface, plus endocytosis and the recycling of ADAM17, occur [14, 17, [22] [23] [24] .
ADAM17 activity is further controlled by interacting molecules, such as tissue inhibitor of metalloprotease 3 [25] , b1-integrins [26] [27] [28] , and secreted frizzled related protein 3 [29] , and by processes such as stimulated release in exosomes [30] .
The shedding activity of ADAM17 is, in addition, regulated by a structural change within its extracellular part. The MPD, with the adjacent located CANDIS region, acts as a regulatory switch for substrate recognition, membrane interaction, and dimerization [12, 20, [31] [32] [33] [34] . CANDIS is part of the stalk region whose hydrophobic side is presumed to bind to membranes [34] . A specific binding of the open conformation of MPD to phosphatidylserine head groups, which are exposed upon various stimuli of ADAM17 to the outer leaflet of the plasma membrane [33] , has been described. This event is thought to be located in the extracellular part in close proximity to the plasma membrane, thereby facilitating the interaction with the membrane-proximal cleavage sites of ADAM17 substrates [1, 2, 35, 36] .
To avoid the occurrence of hyperactive ADAM17 together with the uncontrolled release of cytokines or growth factors, the protease has to be inactivated. Inactivation might occur via endocytosis, followed by degradation, and/or abrogation of substrate recognition by the structural change in its extracellular part. The latter suggestion is based on the isomerization of two disulfide bridges within the MPD, which is catalyzed by protein-disulfide isomerase (PDI), such as PDIA6 [10, [37] [38] [39] . In its active form, ADAM17 contains a flexible open MPD (opMPD) which allows CANDIS to bind to substrates and to interact with the cell membrane [12] . During the inactivation process, PDIA6 catalyzes the isomerization, which results in a compact closed MPD (clMPD), thereby abrogating substrate recognition and membrane binding.
PDIs are proteins that reside in the endoplasmic reticulum (ER) where they assist protein folding by facilitating proper disulfide formation. In addition to their classic function in the ER, PDIs are well-known to act at the cell surface [40] [41] [42] [43] [44] [45] [46] by reducing disulfide bonds. This induces structural changes in the extracellular part of transmembrane proteins such as activating integrins [46, 47] , supporting human immunodeficiency virus-1 cell entry [48, 49] , enabling MHC class I polypeptide-related sequence A processing [41] , and inactivating of the shedding activity of ADAM17 [10, 39] . If ADAM17 is produced in the open, active form, an intriguing question is why PDIs do not catalyze the isomerization in the ER, ending up with an inactive ADAM17. Consequently, mechanisms must exist that protect the open form of ADAM17 against the isomerase activity of ER-resident PDIs. Since many attempts have failed to identify molecules catalyzing the reverse isomerization, protection of the opMPD seems to be highly likely.
The 78-kDa glucose-regulated protein (GRP78), also known as immunoglobulin-binding protein (BiP), is an ER-resident member of the Hsp70 chaperon family. Since it acts as a major switch in the unfolded protein response, its gene deletion in mice unsurprisingly leads to peri-implantation lethality, and these embryos do not hatch from the zona pellucida and fail to grow in culture [50] . Expression of GRP78 is up-regulated in stress situations, such as nutrient depletion, hypoxia, viral infection, and cancer [51] [52] [53] [54] . GRP78 has also been found to be located at the cell surface, and its presence is associated with various tumors [40, [55] [56] [57] . At the cell surface, the chaperon interacts with a number of diverse targets, thereby preventing apoptosis or facilitating viral entry [58] [59] [60] [61] [62] . Moreover, GRP78 has been co-purified with cell surface-localized PDIA6 [41, 63] . Our study is based on the hypothesis that the chaperon GRP78 protects the opMPD of ADAM17 against PDIA6, thereby preventing its inactivation in the ER. The presented data show that ADAM17 and GRP78 directly interact with each other, and that GRP78 is able to suppress the activity of PDIA6 against the opMPD. In agreement, the down-regulation/overexpression of GRP78 leads to the decreased/ increased shedding activity of ADAM17 supporting our hypothesis, although the knock-down of such a central chaperone may result in many defects on the cellular level.
Materials and methods

Immunoprecipitation followed by mass spectrometry
For co-immunoprecipitation, 3 9 10 6 HEK293T cells were seeded in 10-cm culture dishes. After 24 h, the cells were transfected. After an additional 48 h, these cells were stimulated with 100 nM PMA for 5 min and harvested. Cells transiently expressing HE-ADAM17, C-terminal tagged with a PC-tag, were lysed in lysis buffer (20 mM Tris, 150 mM NaCl, 2 mM EDTA, 0.5% Triton X-100, 0.1% SDS, 5 mM CaCl 2 , pH 7.4, and complete protease inhibitor mixture; Roche Applied Science, Mannheim, Germany). The lysates were divided, and the same amounts of lysate were incubated with 30 lL beads coupled with HPC4 antibody (HPC4-beads) or with isotype control antibody (control beads) for 60 min at 4°C. Subsequently, the beads were washed five times with lysis buffer and prepared for SDS/PAGE by heating them for 5 min at 95°C in 60 lL 2.59 L€ ammli buffer (6% SDS, 30% glycerol, 5% b-mercaptoethanol, 150 mM Tris-HCl (pH 6.8), and 0.2% bromophenol blue). From each lane, 6-12 bands were excised that were then subjected to tryptic in-gel digestion by standard protocols. Protein digests were analyzed by liquid chromatography -mass spectrometry (LC-MS) employing a Dionex 3000 HPLC coupled only to an electrospray Orbitrap mass spectrometer to identify interaction partners.
Microscale thermophoresis (MST)
Microscale thermophoresis was performed to measure the binding affinity (K d value) of clMPD or opMPD and GRP78. The fluorescence labeling of the MPDs was performed with the amine-reactive MO-L003 Monolith TM Protein Labeling Kit RED-NHS (NanoTemper Technologies, Munich, Germany) according to the manufacturer's recommended standard protocol. The unlabeled binding partner GRP78 was titrated (31.25 lM to 0.9537 nM, 1 : 2 dilution series) against a constant MPD concentration (100 nM) in HBS-PM buffer (20 mM HEPES, 150 mM NaCl, 0.01% P20, 4 mM MgCl 2 at pH 7.4) containing either 5 mM ADP or ATP. The measurement was performed in replicates (n = 3) with a Monolith NT.115 instrument by using MO-AK005 Monolith TM Premium Coated Capillaries (NanoTemper Technologies) with 20% LED power and 20% MST power at 25°C. The interaction of the MPDs with GRP78 resulted in a dose-dependent ligand-induced fluorescence intensity shift as verified by the recommended SDS-denaturation test (User Guide NT.115; NanoTemper Technologies). Briefly, the first and last three samples of the total 16 samples per measurement were centrifuged (10 min, 15 000 g) to remove potentially precipitated protein causing the observed shift. Next, the supernatant was incubated for 5 min at 95°C including 2% (w/v) sodium dodecyl sulfate and 20 mM dithiothreitol (DTT). The fluorescence intensity of these samples was measured with the Monolith NT.115 instrument as described above, resulting in the same fluorescence intensity (AE 3%) in all samples. Unspecific binding of GRP78 to the RED-NHS dye was tested in replicates (n = 2) by measuring GRP78 (20 lM to 0.61 nM, 1 : 2 dilution series) against 20 nM of the dye alone with the same instrument settings as those described above in HBS-PM containing 5 mM ADP and HBS-P (HBS-PM without MgCl 2 ). The reactive NHS-ester of the dye was inactivated by incubation with a fourfold molar excess of ethanolamine for 30 min at room temperature. The MST analysis and the calculation of the K d values based on the change of the initial fluorescence intensity were performed by using MO. AFFINITY ANALYSIS software v2.2.4 (NanoTemper Technologies) to fit the following equation:
with C GRP78 = concentration of GRP78, C MPD = concentration of MPD, R U = response value of unbound state, R B = response value of bound state, and 
Recombinant proteins
The cDNAs of mature human GRP78 and PDIA6 were cloned into the pET28 plasmid. Proteins were expressed in Escherichia coli BL21 by induction with 1 mM isopropyl b-D-1-thiogalactopyranoside at 37°C. Bacteria were harvested and lysed in 20 mM Tris-HCl, 50 mM KCl, 300 mM NaCl, pH 7.5 in the case of GRP78 or phosphate-buffered saline (PBS) in the presence of cOmplete Protease Inhibitor Cocktail (Roche Diagnostics, Mannheim, Germany) and Benzonase (Santa Cruz Biotechnologies, Heidelberg, Germany) and purified via Ni-HisTrap column (GE Healthcare, Mannheim, Germany). After elution with imidazole, recombinant proteins were further purified by size-exclusion chromatography by using a Superdex 200 16/60 column (GE Healthcare). Recombinant open MPD17 was obtained as described earlier [10] , by using Ni-affinity, size exclusion, and reverse-phase HPLC.
Isomerization of the open MPD17 by PDI
The open form of the membrane-proximal domain (opMPD) of ADAM17 (10 lg) was incubated with the indicated amounts of reduced PDIA6. For reduction, PDIA6 was incubated with 50 mM DTT for 2 h at room temperature. Subsequently, the buffer was exchanged two times by using a NAP TM -5 and NAP TM -10 column (GE Healthcare). The success of DTT removal was tested in representative samples by Elman's test (data not shown). Following buffer exchange, the protein concentration was determined, and 9.7 lg PDIA6 was mixed with 10 lg opMPD (resulting in a molar ratio of 1 : 5 PDIA6 : opMPD) in the presence or absence of GRP78 at the indicated concentrations. The reactions were carried out in isomerization buffer (20 mM TrisHCl pH 7.5, 100 mM NaCl, 50 mM KCl, 5 mM MgCl 2 , and 0.5 mM ATP). The success of the isomerization after 170 min at 37°C was analyzed by reverse-phase HPLC (Bio-200-C18 5l, MultoHigh; CS-Chromatography Service GmbH, Langerwehe, Germany), and the areas of the peaks, corresponding to the open and to the closed form, were determined. The sum of the peak areas was set to 100%, and the percent of the closed isoform was taken as a measure for activity. The mean and the standard deviation of at least three independent experiments were calculated. To inhibit the activity of GRP78, the experiment was either performed in PBS or in isomerization buffer in the presence of 20 lM Hsp70/GRP78 inhibitor VER-155008 (Sigma-Aldrich, Munich, Germany).
GRP78 activity assay
The malachite green assay kit (Abnova, Aachen, Germany or Cayman/Biomol, Munich, Germany) was used to confirm the ATPase activity of recombinant GRP78 in various buffers. Prior to analysis, GRP78 was incubated with ATP 
Insulin turbidity assay
To analyze the activity of PDIA6, 1 mgÁmL À1 insulin in turbidity buffer (100 mM Tris-HCl pH 7.5, 5 mM MgCl 2 , and 0.5 mM ATP) was incubated with 1 lmol of PDIA6 in the presence of 1 mM DTT at 25°C. Prior to the addition of DTT, GRP78 and/or PDIA6 was preincubated for 5 min at 25°C. The turbidity was measured at 650 nm by using a sample without PDIA6 and/or GRP78 as reference.
The experiments represent one out of three independent experiments that showed comparable curve progression.
Cell culture and alkaline phosphatase-based shedding assay by using transiently transfected HEK293T cells
HEK293T cells were cultured in Dulbecco's modified Eagle's medium (DMEM) high-glucose with 10% fetal bovine serum (FBS), streptomycin (100 mgÁL À1 ), and penicillin (60 mgÁL À1 ) (Sigma-Aldrich) and transfected with N-terminally alkaline phosphatase (AP)-tagged human IL-6R. Next day, the cell culture medium was removed, and cells were exposed to ATP-activated GRP78 (60-fold molar excess of ATP) in DMEM. As a control, cells were treated with protein buffer (20 mM Tris, 300 mM NaCl, 50 mM KCl, 5 mM MgCl 2 ) supplemented with ATP. After 30 min of incubation at 37°C, cells were treated for another 30 min with PMA (100 nM; Sigma-Aldrich) in the presence or absence of the metalloprotease inhibitor marimastat (10 lM; SigmaAldrich). Subsequently, the cell supernatant was collected, and the cells were lysed (20 mM Tris, 150 mM NaCl, 2 mM EDTA, 1% Triton X-100, cOmplete Protease Inhibitor Cocktail (Roche Diagnostics), 10 lM marimastat). The AP substrate 4-nitrophenyl phosphate (Sigma-Aldrich) was added to lysates and supernatants, and absorption at 405 nm was measured. The activity of ADAM17 was calculated as described previously [12, 29, 32] . For each GRP78 concentration, the supernatant/lysate ratio was normalized to the value of marimastat-treated samples, and the sample treated with buffer and PMA was set to 100%.
To analyze the effect of GRP78 on the constitutive shedding activity of ADAM17, we performed a comparable experiment, but without addition of PMA. Cells were either treated with 100 lgÁmL À1 GRP78 ( AP ectodomain shedding after VER-155008 treatment of transiently transfected HEK293T cells HEK293T cells were seeded in six-well plates and transfected with AP-coupled IL-6R by using PEI as the transfection reagent. On the following day, the medium was exchanged for medium containing 20 lM VER-155008 (Sigma-Aldrich) or DMSO as a control. After 15 min of incubation at 37°C, cells were stimulated with PMA (100 nM; Sigma-Aldrich) in the absence or presence of the metalloprotease inhibitor marimastat (10 lM; SigmaAldrich). At 2 h after stimulation, the supernatant was harvested, and the cells were lysed (20 mM Tris, 150 mM NaCl, 2 mM EDTA, 1% Triton X-100, cOmplete Protease Inhibitor Cocktail (Roche Diagnostics), 10 lM marimastat). The AP activity of the lysates and supernatants was assessed by measuring the absorption at 405 nm after the addition of the AP substrate 4-nitrophenyl phosphate (Sigma-Aldrich). The supernatant/lysate ratio for each sample was normalized against the value of marimastat-treated samples, and the sample treated with DMSO and PMA was set to 100%. To establish whether VER-155008 had an effect on the shedding activity of ADAM17, cells were treated as described above with DMSO, VER-155008, or VER-155008 in the presence of marimastat but were not co-stimulated with PMA. After 2 h and 15 min, the cells and supernatants were harvested and the relative shedding activity calculated as described above for the co-treatment with VER-155008 and PMA.
AP ectodomain shedding of stably expressing HEK293 cells
The stable HEK293 cell line expressing AP-tagged heparinbinding epidermal growth factor (HB-EGF-AP) [64] was cultured in DMEM with 10% FBS and supplemented with antibiotics at 37°C under a 5% CO 2 atmosphere. For the ADAM17 shedding activity assay, the cells were seeded into a six-well plate and transfected transiently with RNAi oligos [(Scramble (sc-37007) and GRP78si (sc-29338)] or transiently transfected with empty pFLAG and pFLAG-GRP78 pcDNAvector by using the Lipofectamine and Plus reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's protocol. After 24 h, the cells were detached by trypsinization, counted (3 9 10 5 cells per well), and seeded in 24-well plates (Corning, Carlsbad, CA, USA). The following day, the cells were starved for 4 h and activated with PMA (50 ngÁmL
À1
) for 1 h in a phenol-free medium. The cleavage of HB-EGF-AP was measured after overnight incubation of the supernatant with the AP buffer. Briefly, 100 lL conditioned media was collected from each well, added to individual wells of a 96-well plate containing 100 lL AP buffer (0.5 M Tris-HCl, pH 9.5, 5 mM p-nitrophenyl phosphate disodium, 1 mM diethanolamine, 50 lM MgCl 2 , 150 mM NaCl, 5 mM EDTA), and measured at 405 nm. Since the analyzed substrate of ADAM17 was stably transfected, the expression was not normalized by analyzing the lysates. To obtain comparable data, these experiments were performed by using a fixed equal cell number in all cases and were statistically analyzed by one-way ANOVA followed by Tukey's test. Three independent experiments were performed in duplicate.
Western blot
For the detection of the expression of FLAG-tagged GRP78, GAPDH, and ADAM17 on nitrocellulose membrane, proteins were transferred onto the membranes (GE Healthcare) by a semi-dry system (Bio-Rad, Hercules, CA, USA). They were blocked with 5% skim milk for 2 h and incubated either with a-FLAG-specific (Sigma, Hercules, CA, USA), a-GAPDH-specific (1 : 3000; Bethyl), or a-ADAM17-specific (Millipore, Hercules, CA, USA) antibodies for 2 h. The membranes were washed three times, with 10 mL Tris-buffered saline containing 0.05% Tween 20 and then reacted with horseradish-peroxidase-conjugated goat secondary antibodies (1 : 5000; Santa Cruz Biotechnology) for 2 h. After three washes, visualization was achieved by chemiluminescence with an ECL kit (Amersham Biosciences, Hercules, CA, USA).
To confirm GRP78 overexpression or ADAM17 expression, HEK293T cells were lysed (20 mM Tris, 150 mM NaCl, 2 mM EDTA, 1% Triton X-100, cOmplete Protease Inhibitor Cocktail (Roche Diagnostics), 10 lM marimastat), and the protein concentration was determined via BCA assay (Thermo Scientific, Hercules, CA, USA). Each sample was run on a 10% SDS/PAGE (200 V, 75 min), which was blotted (120 V, 120 min, 4°C) onto a PVDF membrane (Merck Millipore, Billerica, MA, USA). Western blots were blocked with 5% BSA in PBS and washed three times in TBST (TBS with 0.05% Tween-20). To detect GRP78 or b-actin, the following antibodies were used: 
Analysis of mRNA expression levels
Total RNA was obtained by using the TRIzol reagent (Invitrogen), and 3 lg total RNA was used for reversetranscription by using a first-strand cDNA synthesis kit (GE Healthcare). Real-time quantitative PCR was performed by using the SYBR Ò Green PCR Master Mix (Applied Biosystems, Carlsbad, CA, USA), and dissociation curves were obtained to confirm the specificity of products. The primer sequences are described in Table 1 . The threshold cycle (C t ) values of targeted genes were normalized relative to the glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene, and relative expression was calculated by the 2-DDC t method. (considering the mean C t ADAM17/mean C t GAPDH). The positive control is composed by a cDNA generated from a pool of samples and it is used for normalization. The C t value obtained for this pool allows the evaluation of intra-assay variation. To correct this variation, the relative expression of the target (ADAM17 or GRP78) and endogenous genes (GAPDH) were obtained by dividing first the C t value of each sample by the C t value in the normalizing sample (pool of samples) for the same gene and the relative C t (target/endogenous gene) was calculated for each individual sample. Three independent experiments were performed in triplicate. Student 0 s t-test was used for real-time analysis.
Flow cytometry and GRP78 overexpression
HEK293T cells were transiently mock-transfected or with GRP78 encoding plasmid. The following day, the cells were stimulated (5, 30, or 90 min) with PMA (100 nM; SigmaAldrich) or DMSO as a control. Subsequently, cells were washed with PBS, and 500 000 cells were used for staining.
To detect human ADAM17, cells were incubated with the antibody A300E [65, 66] 
Results
GRP78 interacts with ADAM17
In order to identify the interaction partners of ADAM17, a proteolytically inactive ADAM17 mutant (HE-ADAM17) was used for co-immunoprecipitation experiments; in this mutant, His415 and Glu406 had been exchanged in the active center [12] . HEK293T Table 1 . Primer sequences used for real-time PCR.
Real-time PCR Primer sequences
cells were transfected with a plasmid encoding C-terminal PC-tagged HE-ADAM17. After 2 days, cells were stimulated for 5 min with PMA, harvested, and lysed. HE-ADAM17 was precipitated by using antibodies against the PC-tag (HPC4) coupled to beads. As a control, half of the lysates was incubated with control beads. The resulting precipitates were subjected to SDS/PAGE. Lanes were sliced and analyzed by mass spectrometry. In addition to known interaction partners of ADAM17, such as PDIA6 [10] , Notch-1 [67] , and b1-integrin [26] , GRP78 was identified with high confidence (Fig. 1A,B) .
GRP78 binds to the MPD with high affinity
Since our hypothesis is that GRP78 protects the MPD of ADAM17 against the activity of PDIs, we examined, by MST, whether these two molecules interacted with each other at all. Therefore, the affinities of GRP78, in the presence of either ATP or ADP, to both forms of the MPD were measured by MST (Fig. 1C,D) . The interaction of the labeled MPDs with GRP78 led to a GRP78 concenctration-dependent shift of the measured initial fluorescence intensity. This was verified by a SDS-denaturation test to exclude protein precipitation or pipetting errors as potential causes (see Materials and methods for details). This fluorescence intensity shift rather than the thermophoresis data had to be used to determine the K d values, as such a strong shift of the initial fluorescence intensity precluded an MST analysis (fitted data shown in Fig. 1C ). GRP78 bound with equally high affinity (K d = 114 AE 35 and 107 AE 36 nM for clMPD and opMPD, see Table 2 ) to both isoforms and did not bind the RED-NHS dye alone (Fig. 1E,F) . Despite the rather small differences of the K d values in relation to the confidence interval, a trend to approximately 40% higher K d values in the presence of ATP as compared with those in the presence of ADP was observed (Fig. 1D) . This was further supported by an approximately 30% decrease (representing a weaker interaction and thus a smaller fluorescence change) of the response amplitude of the ligand-induced fluorescence intensity shift in the presence of ATP (Table 2) .
GRP78 prevents disulfide isomerization of the MPD
To test whether GRP78 interferes with the PDIA6-catalyzed disulfide isomerization of the opMPD, we used recombinant proteins. First, the ATPase activity of recombinant GRP78 was verified in a recommended phosphatase buffer ( Fig. 2A) . Since PDIA6 revealed only low activity in this buffer, an isomerization buffer was used that nevertheless allowed GRP78 to hydrolyze ATP and to release phosphate (Fig. 2B) . Subsequently, the opMPD was incubated with various concentrations of GRP78 and reduced PDIA6. The PDIA6-mediated conversion of the opMPD into the clMPD was analyzed by reversed-phase HPLC (Fig. 2C,D) . PDIA6 alone catalyzed the isomerization of the opMPD disulfide isomer into the closed isomer [10] . We were able to separate the opMPD and clMPD by RP-HPLC. Hereby, the clMPD eluted earlier compared with the opMPD, since the latter is more flexible in its structure and therefore presents more hydrophobic interaction sites with the column. The flexibility and the differences in the pattern of the disulfide bridges have previously been determined by NMR and mass spectrometry [10] . Hence, the isomerization of the opMPD to the clMPD becomes apparent in that the area of the peak representing the opMPD decreased, whereas the area of the peak representing the clMPD increased compared with the control (opMPD without PDIA6). This was counteracted by the addition of GRP78, showing that GRP78 protected the opMPD against the disulfide isomerization by PDIA6. This effect was concentration-dependent, since an excess of GRP78 (2.5 : 1 relative to opMPD) completely abrogated the isomerization, whereas a one to one ratio of opMPD and GRP78 (1 : 1 ratio relative to opMPD) protected the opMPD against the catalytic activity of PDIA6, and a fivefold reduced amount of GRP78 (0.2 : 1 relative to opMPD) reduced the activity of PDIA6 by approximately 50% only (Fig. 2C,D) . This suggested the formation of a stable hetero-dimeric complex between GRP78 and MPD. Preincubation of opMPD with GRP78 in the presence of ATP at 37°C for 30 min, prior to the addition of PDIA6, did not alter the protective effect of GRP78 (data not shown).
As GRP78 is a member of the Hsp70 family, its substrate binding is often linked to its ATPase activity, whereby substrate binding leads to ATP hydrolysis. Release of ADP and the binding of a new ATP molecule induces the substrate release and subsequently enables GRP78 to undergo a new interaction [68, 69] . To test whether the absence of ATP and the presence of phosphate influence the protection of the opMPD by GRP78, the isomerization experiments were performed in PBS without the addition of ATP. These experiments revealed that an excess of phosphate and the absence of exogenous ATP did not abrogate GRP78 protection of the opMPD against PDIA6 activity (Fig. 2E) . To test whether the ATPase activity of GRP78 was indeed unnecessary for protection, this experiment was repeated in isomerization buffer in the absence of ATP and in the presence of an inhibitor of GRP78, namely VER-155008 [70] [71] [72] . In the presence of its inhibitor, GRP78 also suppressed the isomerase activity of PDIA6 against opMPD indicating that ATPase activity was not needed for this process (Fig. 2F) .
GRP78 does not inhibit PDIA6 activity in general
To analyze whether GRP78 was able to inhibit PDIA6 activity in general, or whether this inhibition was specific for the opMPD, an insulin turbidity assay was performed in the presence or absence of GRP78 and/ or PDIA6. The precipitation of insulin in the presence of DTT, catalyzed by PDIA6, was detected relative to a reference cuvette at 650 nm. The experiment was performed in a turbidity buffer, which allowed the precipitation of insulin and GRP78 ATPase activity (Fig. 2B) . PDIA6 reduces the disulfide bonds of insulin, which then aggregates and precipitates. This was not significantly altered in the presence of GRP78. Neither a 1 : 1 nor a 1 : 5 ratio of PDIA6 to GRP78 resulted in a significantly altered precipitation of insulin. In contrast, GRP78 alone seemed to prevent the aggregation of insulin, since the turbidity occurred more slowly compared with that in the reference sample without GRP78 (Fig. 2G,H) . These results indicated that GRP78 neither influenced the activity nor directly interacted with PDIA6. This was supported by surface plasmon resonance (SPR) measurements showing no interaction of GRP78 with PDIA6 (data not shown).
Influence of GRP78 on ADAM17 activity
Since GRP78 is present on the cell surface and interacts with ADAM17, we analyzed the impact of exogenously added GRP78 (preincubated with ATP) on the shedding activity of ADAM17. HEK293T cells were transfected with AP-tagged human IL-6R, which is well-known to be cleaved by ADAM17 upon treatment with PMA [73] . Three different concentrations of recombinant GRP78/ATP complex were added 30 min prior to the stimulation of the shedding activity of ADAM17 by the addition of PMA. After 30 min of PMA stimulation, the cells where harvested, and the shedding activity was analyzed. Only a slight increase in shedding activity was observed at a very high, nonphysiological concentration of 100 lgÁmL À1 GRP78 that was exogenously added (Fig. 3A) . To examine the influence of endogenous GRP78 on the shedding activity of ADAM17, cells were treated with an inhibitor of GRP78 (VER-155008 [70] [71] [72] ) at 15 min prior to and during stimulation of ADAM17 (Fig. 3B) . Interestingly, inhibition of endogenous GRP78 activity indeed led to a reduction in ADAM17-mediated shedding, supporting the hypothesis that GRP78 protected ADAM17 against the inactivating action of PDIs. This protection results in a stabilization of the active conformation. In contrast, the inactivation of GRP78 by VER-155008 might result in a higher accessibility of PDIs for the MPD resulting in an increase of inactive ADAM17; this explains the lower shedding activity in the VER-155008 co-treated cells by PMA stimulation. In contrast to the inactivation of ADAM17 by marimastat, which targets directly the catalytic center, inhibition by VER-155008 targets indirectly the PDI catalyzed disulfide-bound isomerization in the MPD, which is in agreement with a slower and a smaller inhibitory effect of VER-155008-treated samples compared with those treated with marimastat. To rule out that the presence of VER-155008 decreases the shedding activity of ADAM17, transfected cells were treated only with DMSO, VER-155008, or VER-155008 in the presence of the metalloprotease inhibitor marimastat. Following 2 h and 15 min, the supernatants and cells were harvested, and the shedding activity was determined (Fig. 3C) . Whereas the co-treatment of cells with VER-155008 and PMA decreased the PMA-induced shedding activity of ADAM17, the constitutive shedding activity was slightly increased. This increase was lower than twofold. However, as PMA increases the shedding activity of ADAM17 about 20-fold compared with the DMSO control sample, the increased effect of VER-155008 is insignificant for this short-time treatment.
To confirm the relevance of endogenous GRP78 levels further, the effects of overexpressing and silencing GRP78 on ADAM17 activity were analyzed in HEK293 cells stably expressing AP-tagged HB-EGF, another substrate of ADAM17. These cells were transiently transfected with FLAG-tagged GRP78 or empty vector and treated with PMA. Overexpression of FLAG-tagged GRP78 resulted in a significantly higher shedding activity of ADAM17 compared with untransfected cells (Fig. 3D , P < 0.05, one-way ANOVA followed by Tukey's test). Given that stably expressing cells were used in this experiment, we measured the absorption of the supernatants at 405 nm. In contrast to the previously presented experiments, where cells transiently transfected with the AP-tagged IL-6R were used. Hereby, the absorption had to be normalized for evaluation because of the variation of transfection efficiency between the different experiments. Western blotting confirmed the expression of FLAG-tagged GRP78 (Fig. 3E) . The effect of exogenously added GRP78 was also verified with these cells. Recombinant GRP78 (1 lM, approximately 70.5 lgÁmL À1 ) was added prior to PMA activation and led to an increase in HB-EGF shedding compared with the PBS-treated control (PBS, treated) ( Fig. 3F , P < 0.05, one-way ANOVA followed by Tukey's test).
To confirm the influence of GRP78 on ADAM17 further, the expression of GRP78 in HEK293 cells, which stably expressed AP-tagged HB-EGF, was down-regulated by siRNA. Since a complete knockdown of GRP78 expression is lethal for the cells, and since even a strong reduction of GRP78 results in severe cellular defects [50] , only a moderate reduction can be achieved. The targeted knock-down of GRP78 decreased HB-EGF shedding by 58% in relation to scrambled siRNA ( Fig. 3G , P < 0.05, one-way ANOVA followed by Tukey's test), although only a reduction of 34% of GRP78 expression was attained (Fig. 3H , P < 0.05, Student's t-test and Fig. 3I) . Noteworthy, the down-regulation of GRP78 did not affect the ADAM17 mRNA level (Fig. 3H) as established by real-time polymerase chain reaction (PCR).
ADAM17 has to be stimulated to become proteolytic active, but GRP78 might enhance its low constitutive shedding activity. To address this, a shedding assay in which cells were treated with a mixture of GRP78 (100 lgÁmL À1 = 1.28 mM) and a 60-fold excess of ATP (76.8 mM) for 6 h was performed. As a control, we incubated the cells only with ATP (76.8 mM). These two conditions were each run with and without marimastat as an inhibitor of shedding activity (Fig. 3J ). Upon harvesting of supernatant and cells, the shedding activity was determined as described in the Materials and methods section. These experiments showed a low constitutive shedding activity of ADAM17 which was not significant influenced by the addition of exogenous GRP78.
GRP78 activity is needed for cell surface expression of ADAM17
The supportive effect of GRP78 on the activity of ADAM17 might be the result of an increased lifetime of ADAM17 on the cell surface. Nonactivated cells store most of their ADAM17 in intracellular compartments. The transport of ADAM17 to the cell surface can be stimulated by PMA followed by internalization and degradation [14, 17, [22] [23] [24] 29] . To examine the effect of GRP78 on the cell surface presence of ADAM17, HEK293T cells were either mock-transfected or transfected with a GRP78-encoding plasmid. The increased expression of GRP78 was confirmed by Western blot analysis (Fig. 4A) . Although GRP78 expression was clearly up-regulated, flow cytometry analysis revealed that the increased expression of GRP78 did not alter the amount of ADAM17 on the cell surface significantly, independently of whether these cells were stimulated with PMA or not (Fig. 4B,  C) . Figure 4D presents the summary of three independent experiments shown in Fig. 4B ,C. Since the overexpression of GRP78 had no effect on the presence of ADAM17 on the cell surface, the basal expression level of the chaperon might be high enough to protect endogenous ADAM17. To analyze whether the catalytic activity of GRP78 is needed for correct ADAM17 synthesis, HEK293T cells were treated with an inhibitor of GRP78 (VER-155008 [70] [71] [72] ) for 1 or 2 days, and ADAM17 cell surface presence was analyzed by flow cytometry (Fig. 5A,B) . The obtained data showed a reduced presence of ADAM17 on the Fig. 3 . Analysis of the shedding activity of ADAM17 during GRP78 overexpression and exogenous addition of recombinant GRP78 and GRP78 silencing in HEK293 cells stably expressing AP-tagged HB-EGF. (A) Recombinant GRP78 slightly increases activity of ADAM17. One day prior to stimulation, HEK293T cells were transfected with AP-tagged human IL-6R as substrate of ADAM17. At 30 min before stimulation, medium was replaced, and recombinant GRP78 and ATP were added at the indicated concentrations. Activity of ADAM17 was induced by the addition of PMA. After 30 min, cells and supernatant were harvested, and shedding activity was analyzed. The P-value were calculated; the differences between the buffer-treated sample and the sample treated with 100 lgÁmL À1 GRP78 were considered as significant at a P-value of 0.03. (B) Inhibition of the catalytic activity of GRP78 leads to a decrease in the shedding activity of ADAM17. HEK293T-cells were transfected with AP-tagged IL-6R. One day later, the cells were preincubated with VER-155008 and then stimulated as indicated. After 2 h, supernatant and cells were harvested, and the catalytic activity was analyzed as described in Materials and methods.
(C) VER-155008 increases the constitutive shedding less than twofold. To analyze the effect of VER-155008 on the shedding activity of ADAM17, cells transfected with AP-tagged IL-6R were treated either with DMSO, with VER-155008, or with VER-155008 in the presence of marimastat. Following 2 h and 15 min, cells and supernatant were harvested, and the shedding activity determined as described above.
(D) Cells were transfected with an empty vector (pFLAG) or pFLAG-GRP78. After 1 day of transfection, cells were harvested, and defined numbers of cells were seeded into a multi-well plate. After one additional day, the cells were treated with PMA or DMSO, and soluble APtagged HB-EGF was quantified in the supernatant. Three independent experiments in triplicate were performed (n = 3, one-way ANOVA followed by Tukey's test, *P < 0.05). (E) Upper panel shows the result of real-time PCR (qPCR), which confirmed the overexpression of GRP78 after transient transfection with pFLAG-GRP78 vector. Three independent experiments in triplicate were performed (n = 3, Student's t-test, *P < 0.05). Real-time PCR (qPCR) also indicates that the transient transfection of pFLAG-GRP78 vector does not affect ADAM17 expression (ns = not significant). Lower panel shows an anti-FLAG immunoblot that confirms the overexpression of FLAG-tagged GRP78 in cells transfected with pFLAG-GRP78. (F) HEK293 cells stably expressing the chimeric construction HB-EGF fused to AP were treated with PBS or 1 lM GRP78 recombinant protein in serum-free media. After 4 h of treatment, cells were stimulated with PMA (50 ngÁmL À1 ) or DMSO. Quantification of shed AP-tagged HB-EGF in the supernatant revealed an increase in the shedding activity of ADAM17 in the presence of GRP78. Three independent experiments in triplicate were performed (n = 3, one-way ANOVA followed by Tukey's test, *P < 0.05). (G) Shedding activity of ADAM17 in cells that were transfected with scrambled RNAi oligonucleotides (siSCR) and GRP78 RNAi oligonucleotides (siGRP78). Three independent experiments in triplicate were performed (n = 3, one-way ANOVA followed by Tukey's test, *P < 0.05). (H) Real-time PCR (qPCR) confirmed the inhibition of GRP78 expression after transient transfection with siRNA oligonucleotides targeting GRP78. Three independent experiments in triplicate were performed (n = 3, Student's t-test, *P < 0.05). Real-time PCR (qPCR) also indicates that the transient transfection of oligonucleotides against GRP78 does not affect ADAM-17 expression (ns = not significant).
(I) Anti-GRP78 immunoblotting confirmed the silencing of GRP78 in cells transfected with siGRP78. (J) Analysis of the influence of exogenous GRP78 on the constitutive shedding activity of ADAM17. HEK293T cells transfected with AP-tagged IL-6R were incubated either with ATP alone (76.8 mM) or with a mixture 100 lgÁmL À1 GRP78 (1.28 mM) with a 60-fold molar excess of ATP (76.8 mM) in the presence or absence of the metalloprotease inhibitor marimastat. After 6 h, AP activity was determined as described above and normalized regarding the shedding activity of the corresponding sample marimastat-treated sample to evaluate the constitutive shedding activity. transmembrane proteins in general, the same experiments were performed, whereby cells were treated for 1 day with VER-155008 and were stained for the transferrin receptor (Fig. 5C ). These data indicate that, in contrast to ADAM17, the expression of the transferrin receptor was not significantly influenced by the suppression of GRP78 activity. In summary, these data indicate that, upon inhibition of GRP78 by VER-155008, ADAM17 is less effectively protected from PDIA6-induced inactivation. Since inactivated ADAM17 is likely to be degraded, the inhibition of GRP78 will consequently lead to decreased ADAM17 cell surface expression.
Analysis of ADAM17 expression in lysates from VER-155008-treated cells by Western blot did not show any differences in the total expression level of the protease (Fig. 5D ) in the remaining cells of the flow cytometry analysis shown in Fig. 5A . This might be because ADAM17 has a long half-life time in combination with the low turnover rate in unstimulated cells. Hence, the amount of newly expressed protease might be low. Additionally, most of the ADAM17 is stored intracellularly in its immature form, and without overexpression and stimulation of cells by, for example, PMA, only a small amount of mature ADAM17 is translocated to the cell surface and is subsequently degraded [17, [22] [23] [24] . Since VER-155008 suppresses the activity of HSP70 chaperons, it might influence cellular vitality. Hence, the number of apoptotic cells in the VER-155008-treated cell population was compared with that of DMSO-treated cells after 2 days by incorporation of propidium iodide. Analysis by flow cytometry revealed that no enhanced apoptosis occurred attributable to the presence of VER-155008 during the growth of HEK293T cells, which showed about 40% apoptotic cells upon preparation (Fig. 5E) . Although the suppression of GRP78 activity did not reduce the amount of ADAM17 at the protein level in HEK293T cells (Fig. 5D) , the down-regulation of GRP78 expression by siRNA reduced the total quantity of ADAM17 compared with that in scrambled transfected HEK293 cells (Fig. 5F ). This cell line shows clearly a much higher percentage of mature ADAM17 compared to pro-ADAM17 than HEK293T cells (Fig. 5D) . This difference might be due to different turnover rates of ADAM17 in these cell lines and point to a more dynamic one in HEK293 cells (Fig. 5F ) which might be therefore more sensitive to reduced GRP78 activity than HEK293T cells.
GRP78 is an ER-resident protein with a KDEL motif, most of it being stored intracellularly. If GRP78 protects ADAM17 on the cell surface upon PMA treatment, its cell surface presence probably also increases because of PMA treatment. Hence, the cell surface presence of this chaperon was analyzed by flow cytometry upon PMA treatment of HEK293T cells. We detected only the cell surface-localized GRP78 of nonpermeabilized cells, which were stimulated for different durations (Fig. 5G,H) . In contrast to ADAM17, whose cell surface presence increased in the first few minutes of stimulation, the cell surface presence of GRP78 was not altered within 30 min, indicating that a parallel transport of the chaperon and ADAM17 was not likely, and that the observed effect might be attributable to the protection of endogenous ADAM17 in this experimental setup, although exogenously added GRP78, at a rather high concentration, resulted in a slight increase in the activity of ADAM17. This indicates that GRP78 might be, in general, able to stabilize ADAM17 at the cell surface. The identification of such situations, e.g., in cancer cells, will be a demanding task for future work.
Discussion
Because of the danger of excessive substrate release, the shedding activity of ADAM17 is strictly controlled at several levels. Once activated, ADAM17 processes its substrates on the cell surface. There, it is thought to be inactivated by extracellularly located PDIs that catalyze an isomerization of two disulfide bridges within the extracellular part [10, [37] [38] [39] , a process that renders the active conformation of ADAM17 into an inactive closed form [10] . This mechanism might be used to protect against pathological situations, such as chronic inflammation or cancer progression, to which the prolonged activation of ADAM17 contributes.
As a type-I transmembrane protein, the protease is transported into the ER, where N-glycosylation occurs and disulfide bridges are formed. Since the concentration of PDIs is high in the ER, it is astonishing that ADAM17 exists in an active form on the cell surface and is not inactivated in the ER by PDIs. Therefore, we proposed a protective mechanism with GRP78 as the perpetrator, preventing this isomerization.
By a mass spectrometry-based approach, we have identified GRP78 as an interaction partner of ADAM17, a HSP70-like chaperon mainly located in the ER, which binds proteins in a reversible ATPdependent manner. The chaperon interacts with both isolated isomers of the sole MPD with high affinity. Noteworthy, no significant difference has been found in the affinity of the opMPD and clMPD toward GRP78. Whether the protection is the sole task of GRP78, or whether it is additionally needed for the proper folding of the protease remains to be shown.
Since GRP78 consists of two domains, namely one nucleotide-binding and one substrate-binding domain, use of these single domains may shed light on its various tasks.
The two disulfide bridges, which undergo isomerisation, are in case of the opMPD in a sequential order and directly adjacent [10] . The four involved cysteines span 40 amino acid residues, the last three of them only 10. The PDI induced isomerisation leads to the clMPD in which these disulfide bridges are in an overlapping order [10] . Since disulfide bridges can be formed spontaneously, it is most likely, that they form in the opMPD co-translational during translation into the ER and independently of PDIs. In case of misfolding ADAM17 is a client of PDIA3, which act together with the two chaperon's calnexin or calreticulin [74] . If these chaperons or GRP78 are protecting the opMPD against the isomerase activity of PDIA3 remains open. Since we do not detect PDIA3, calnexin or calreticulin in our initial precipitation experiments, their interaction, if there is one, seems to be of lower affinity than those to GRP78.
At least two arguments indicate that GRP78 has to release ADAM17 on its way through the secretory pathway toward the cell surface. First, GRP78 is located in the ER and contains a KDEL sequence; therefore, it will be transported back from the Golgi apparatus into the ER under resting circumstances. Second, PDIs are able to reduce the activity of ADAM17 at the cell surface of stimulated cells [39] , and consequently, the protective interaction of GRP78 to ADAM17 must be abrogated. One possible mechanism of release of ADAM17 by GRP78 might be the drop in pH when GRP78 travels with ADAM17 to the Golgi apparatus. However, a more likely scenario might be the involvement of additional players that regulate the activity of GRP78, such as ER-resident J proteins, nucleotide exchange factors [68, 69, [75] [76] [77] [78] , or iRhoms.
The negative effect of GRP78 on the activity of PDIA6 against the opMPD was established with recombinant proteins and appears to be specific, since the reduction of insulin by PDIA6 was not significantly influenced by the presence of GRP78.
PMA is a strong activator of the shedding activity of ADAM17, and in contrast to thrombin receptor agonistic peptide (TRAP-6) or histamine-activating histamine receptor H1, the treatment of HEK293T cells with 100 nM PMA results in an increase of ADAM17 at the cell surface, which is followed by clathrin-dependent endocytosis and lysosomal degradation [24] . This degradation might be a safety mechanism acting against the uncontrolled and dangerous release of inflammatory mediators and/or growth factors by ADAM17. This PMA-dependent effect has been inconsistently reported [14, 17, 22] and might be dependent on the cell type and the amount of PMA. In agreement, the treatment of COS7 cells with 40 nM (25 ngÁmL À1 ) PMA still allows shedding upon 2 h of stimulation, but with a lower increase than at earlier time points [16] . Because the overexpression of GRP78 has no effect on the amount of ADAM17 on the cell surface, one might conclude that the basal GRP78 expression is high enough to protect the open form of ADAM17. In agreement with this, the presence of ADAM17 on the cell surface decreases because of the inhibition of the ER-resident GRP78 and the cytosolic HSP70, and the down-regulation of GRP78 reduces the amount of ADAM17 on the protein level but not on the mRNA level. This further indicates that GRP78 activity is a prerequisite for the stability and proper transport of ADAM17 to the cell surface. The lack of GRP78 activity might allow PDIs to catalyze the isomerization of ADAM17, thereby destabilizing the protease and finally leading to its degradation. Unfortunately, conformation-specific antibodies for distinguishing between the open and the closed domain are not yet available for studying the fate of the various isomers. Whether the protease can be reactivated by a reverse isomerization and possibly recycled remains unclear. Alternatively, the PDI-catalyzed isomerization might be a signal to stop recycling and to target degradation in the lysosome.
However, GRP78 is known to occur at the cell surface under various conditions of cellular stress, such as nutrient depletion or hypoxia. These conditions are generic in tumors, and the cell surface presence of GRP78 is well-known to be up-regulated under these conditions. Since the activity of ADAM17 is also wellknown to be up-regulated in various tumors, it is tempting to assume that GRP78 protects ADAM17 on the cell surface of tumors cells against the inactivation by PDIs. In agreement, the reduced expression of PDIA6 increases ADAM17 activity in a glioblastoma cell line and increases its invasive behavior; in this context, the expression and activity of MMP2 are up-regulated in an ERK-dependent way [79] . In contrast, the down-regulation of GRP78 expression in a hepatocyte carcinoma cell line reduces its invasiveness; in this case, the expression and activity of MMP2 decreases, and the activity of the ERK-dependent pathway is reduced [80] . Since the activity of ADAM17 is shown to promote the expression and activity of MMP2 via an ERK-dependent pathway [81] , one might speculate that the GRP78-promoted invasiveness depends on the activity of ADAM17. At least the inhibition of the activity of GRP78 leads to a reduced shedding activity of ADAM17 on the cell surface of HEK293T cells. This finding suggests that GRP78 and PDIs have reverse actions in the regulation of ADAM17. 
